Embolism

• 

  Subject Areas on Research

  • A clinician's perspective of emerging P2Y(12)-directed pharmacotherapies, ex vivo measurement tools, and clinical outcomes. 
  • A multicenter, randomized trial of coronary angioplasty versus directional atherectomy for patients with saphenous vein bypass graft lesions. CAVEAT-II Investigators. 
  • A randomized clinical trial to evaluate the efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valve and atrial fibrillation or flutter: Rationale and design of the RIVER trial. 
  • Ablation of atrial fibrillation during coronary artery bypass grafting: Late outcomes in a Medicare population. 
  • Acute peripheral arterial occlusion: predictors of success in catheter-directed thrombolytic therapy. 
  • Acute retinal arteriolar emboli after cardiac catheterization. 
  • Adjunctive use of the Rinspiration system for fluidic thrombectomy during primary angioplasty: the Rinspiration international registry. 
  • Alternative calculations of individual patient time in therapeutic range while taking warfarin: results from the ROCKET AF trial. 
  • An introduction to transoesophageal echocardiography: II. Clinical applications. 
  • Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. 
  • Anticoagulation Type and Early Recurrence in Cardioembolic Stroke: The IAC Study. 
  • Anticoagulation: choosing the optimal anticoagulant. 
  • Anticoagulation: indications and risk classification schemes. 
  • Anticoagulation: managing adverse events in patients receiving anticoagulation and perioperative care. 
  • Anticoagulation: monitoring of patients receiving anticoagulation. 
  • Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine: A Secondary Analysis of a Randomized Clinical Trial. 
  • Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial. 
  • Apixaban in patients with atrial fibrillation and prior coronary artery disease: insights from the ARISTOTLE trial. 
  • Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. 
  • Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation. 
  • Association between surgical indications, operative risk, and clinical outcome in infective endocarditis: a prospective study from the International Collaboration on Endocarditis. 
  • Atheroembolic involvement of renal allografts. 
  • Atrial septal aneurysm: association with cerebrovascular and peripheral embolic events. 
  • Atrial septal aneurysm: recognition and clinical relevance. 
  • Biomarkers in atrial fibrillation: investigating biologic plausibility, cause, and effect. 
  • Blood pressure control and stroke or bleeding risk in anticoagulated patients with atrial fibrillation: Results from the ROCKET AF Trial. 
  • Cardiac troponin is associated with cardiac outcomes in men and women with atrial fibrillation, insights from the ARISTOTLE trial. 
  • Cardiovascular risk factors for retinal vein occlusion and arteriolar emboli: the Atherosclerosis Risk in Communities & Cardiovascular Health studies. 
  • Central retinal artery occlusion during cardiac catheterization. 
  • Characterizing major bleeding in patients with nonvalvular atrial fibrillation: a pharmacovigilance study of 27 467 patients taking rivaroxaban. 
  • Chronic obstructive pulmonary disease in patients with atrial fibrillation: Insights from the ARISTOTLE trial. 
  • Clinical Characteristics, Oral Anticoagulation Patterns, and Outcomes of Medicaid Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF I) Registry. 
  • Clinical and Economic Outcomes Among Nonvalvular Atrial Fibrillation Patients With Coronary Artery Disease and/or Peripheral Artery Disease. 
  • Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial. 
  • Closed mitral valvotomy for mitral restenosis: experience in 113 consecutive cases. 
  • Complications related to percutaneous transvenous mitral commissurotomy. 
  • Contemporary outcomes after distal vertebral reconstruction. 
  • Coronary embolism and calcified aortic valve: is there a correlation? 
  • Current best practices and guidelines. Assessment and management of complications in infective endocarditis. 
  • Cutaneous cholesterol embolism of the lower extremities. 
  • D-dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation--observations from the ARISTOTLE trial. 
  • Dabigatran or Aspirin After Embolic Stroke of Undetermined Source in Patients With Patent Foramen Ovale: Results From RE-SPECT ESUS. 
  • Defining risk variables causing gas embolism in loggerhead sea turtles (Caretta caretta) caught in trawls and gillnets. 
  • Delivery of glycoprotein IIb/IIIa inhibitor therapy for percutaneous coronary intervention: why not take the intracoronary highway? 
  • Early Elevated Troponin Levels After Ischemic Stroke Suggests a Cardioembolic Source. 
  • Early Risks of Death, Stroke/Systemic Embolism, and Major Bleeding in Patients With Newly Diagnosed Atrial Fibrillation. 
  • Early ischaemic and haemorrhagic complications after atrial fibrillation-related ischaemic stroke: analysis of the IAC study. 
  • Early predictors of in-hospital death in infective endocarditis. 
  • Echocardiographic documentation of vegetative lesions in infective endocarditis: clinical implications. 
  • Echocardiography for the detection of cardiac sources of embolism in patients with stroke or transient ischemic attack. 
  • Economic impact of new interventional therapies: are we asking the right questions? 
  • Edoxaban versus warfarin in patients with atrial fibrillation. 
  • Effectiveness and Safety of Anticoagulants in Adults with Non-valvular Atrial Fibrillation and Concomitant Coronary/Peripheral Artery Disease. 
  • Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial. 
  • Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. 
  • Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. 
  • Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials. 
  • Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). 
  • Efficacy and safety of rivaroxaban compared with warfarin in patients with carotid artery disease and nonvalvular atrial fibrillation: Insights from the ROCKET AF trial. 
  • Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF. 
  • Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial). 
  • Embolic central retinal artery occlusion after subcutaneous auricular steroid injection. 
  • Embolic protection and platelet inhibition during renal artery stenting. 
  • Embolism after inferior vena cava filter mesh fragmentation. 
  • Embolization of cardiac mural thrombus: complication of intraarterial fibrinolysis. 
  • Embolization of patent foramen ovale closure devices: incidence, role of imaging in identification, potential causes, and management. 
  • Emergent cardiac surgery during transcatheter aortic valve implantation (TAVI): a weighted meta-analysis of 9,251 patients from 46 studies. 
  • End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experience. 
  • Estimation and testing of the relative risk of disease in case-control studies with a set of k matched controls per case with known prevalence of disease. 
  • Evaluation of embolization distal to arterial occlusion by transcatheter electrocoagulation (TCEC) and Gianturco coils. 
  • Examining biology and pharmacology-based hypotheses in the PLATO trial. 
  • Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). 
  • Guideline-directed therapies for comorbidities and clinical outcomes among individuals with atrial fibrillation. 
  • Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial. 
  • Homocysteine and retinal emboli: the Blue Mountains Eye Study. 
  • Homocysteine testing in patients with acute ischemic stroke. 
  • How well does physician risk assessment predict stroke and bleeding in atrial fibrillation? Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). 
  • Improved microsurgical anastomotic patency with low molecular weight heparin. 
  • Increased Left Atrial Appendage Density on Computerized Tomography is Associated with Cardioembolic Stroke. 
  • Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale: From the COMBINE AF (A Collaboration between Multiple institutions to Better Investigate Non-vitamin K antagonist oral anticoagulant use in Atrial Fibrillation) Investigators. 
  • Infarct size and left ventricular function in the PRoximal Embolic Protection in Acute myocardial infarction and Resolution of ST-segment Elevation (PREPARE) trial: ancillary cardiovascular magnetic resonance study. 
  • Inferior myocardial infarction complicated by mural thrombus and systemic embolization despite anticoagulation in progressive systemic sclerosis with normal coronary arteriograms. 
  • Interacting medication use and the treatment effects of apixaban versus warfarin: results from the ARISTOTLE Trial. 
  • Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the Intracoronary Eptifibatide (ICE) Trial. 
  • Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation. 
  • Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. 
  • Left ventricular systolic dysfunction, heart failure, and the risk of stroke and systemic embolism in patients with atrial fibrillation: insights from the ARISTOTLE trial. 
  • Long-Term Embolic Outcomes After Detection of Left Ventricular Thrombus by Late Gadolinium Enhancement Cardiovascular Magnetic Resonance Imaging: A Matched Cohort Study. 
  • M-mode echocardiographic observations during and after healing of active bacterial endocarditis limited to the mitral valve. 
  • M-mode echocardiographic observations in active bacterial endocarditis limited to the aortic valve. 
  • Major complications associated with transcatheter atrial septal occluder implantation: a review of the medical literature and the manufacturer and user facility device experience (MAUDE) database. 
  • Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures. 
  • Manual high-dose regional intraoperative thrombolysis of lower extremity emboli after open repair of a ruptured abdominal aortic aneurysm. 
  • N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). 
  • Noncentral Nervous System Systemic Embolism in Patients With Atrial Fibrillation: Results From ROCKET AF (Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). 
  • Novel emboli protection cannula during cardiac surgery: first animal study. 
  • On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF. 
  • Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). 
  • Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trial. 
  • Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial. 
  • Pathologic quiz case: acute-onset paraplegia in a 60-year-old woman. Spinal cord infarction secondary to fibrocartilaginous (intervertebral disk) embolism. 
  • Patient-Level Analysis of Watchman Left Atrial Appendage Occlusion in Practice Versus Clinical Trials. 
  • Patterns of Anticoagulation Use and Cardioembolic Risk After Catheter Ablation for Atrial Fibrillation. 
  • Percutaneous Thrombectomy in Patients with Occlusions of the Aortoiliac Segment: A Case Series. 
  • Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. 
  • Periprocedural Pericardial Effusion Complicating Transcatheter Left Atrial Appendage Occlusion: A Report From the NCDR LAAO Registry. 
  • Predictors of outcome of percutaneous excimer laser coronary angioplasty of saphenous vein bypass graft lesions. The Percutaneous Excimer Laser Coronary Angioplasty Registry. 
  • Prevalence and Associations of Retinal Emboli With Ethnicity, Stroke, and Renal Disease in a Multiethnic Asian Population: The Singapore Epidemiology of Eye Disease Study. 
  • Prevalence and risk factors of retinal arteriolar emboli: the Singapore Malay Eye Study. 
  • Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. 
  • Primary intraaortic malignancy--a case report. 
  • Racial/ethnic differences in atrial fibrillation symptoms, treatment patterns, and outcomes: Insights from Outcomes Registry for Better Informed Treatment for Atrial Fibrillation Registry. 
  • Randomized comparison of primary percutaneous coronary intervention with combined proximal embolic protection and thrombus aspiration versus primary percutaneous coronary intervention alone in ST-segment elevation myocardial infarction: the PREPARE (PRoximal Embolic Protection in Acute myocardial infarction and Resolution of ST-Elevation) study. 
  • Reduced valve replacement surgery and complication rate in Staphylococcus aureus endocarditis patients receiving acetyl-salicylic acid. 
  • Reducing the risk of oral contraceptive-induced thrombosis. 
  • Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial. 
  • Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. 
  • Response to letter regarding article, "renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study cohorts". 
  • Retinal arteriolar emboli and long-term mortality: pooled data analysis from two older populations. 
  • Retinal arteriolar emboli: epidemiology and risk of stroke. 
  • Right ventricular infarction complicated by acute right-to-left shunting. 
  • Risk Profile and 1-Year Outcome of Newly Diagnosed Atrial Fibrillation in Japan　- Insights From GARFIELD-AF. 
  • Risk of stroke and bleeding in relation to hypertension in anticoagulated patients with atrial fibrillation: a meta-analysis of randomised controlled trials. 
  • Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. 
  • Rivaroxaban versus warfarin in patients with atrial fibrillation enrolled in Latin America: Insights from ROCKET AF. 
  • Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. 
  • Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation. 
  • Selective Serotonin Reuptake Inhibitors and Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: An Analysis From the ROCKET AF Trial. 
  • Termination Based on Event Accrual in Per Protocol Versus Intention to Treat in the ROCKET AF Trial. 
  • The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristics. 
  • The clinical impact of incomplete left atrial appendage closure with the Watchman Device in patients with atrial fibrillation: a PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation) substudy. 
  • The risk for systemic embolization associated with percutaneous balloon valvuloplasty in adults. A prospective comprehensive evaluation. 
  • Thrombotic and cardiovascular complications related to nonionic contrast media during cardiac catheterization: analysis of 8,517 patients. 
  • Transesophageal echocardiography before cardioversion. 
  • Transesophageal echocardiography in diagnosing cardioembolic stroke. 
  • Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin: A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis. 
  • Uncommon Cause of Fever and Embolism: Staphylococcus epidermidis Infected Myxoma. 
  • Urologic surgery. 
  • Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial. 
  • Value of transthoracic echocardiography in predicting embolic events in active infective endocarditis. Duke Endocarditis Service. 
  • Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial. 
  • Vegetations in endocarditis: big is bad, but is there more to it? 
  • Warfarin and acetaminophen interaction: a summary of the evidence and biologic plausibility. 
• 

  Keywords of People

  • Alexander, John Hunter Peel, Professor of Medicine, Medicine, Cardiology
  • O'Connor, Christopher Michael, Richard Sean Stack, M.D. Distinguished Professor, Medicine, Clinical Pharmacology